Hal K. Berman
University of California, San Francisco
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hal K. Berman.
Cancer Research | 2005
Mona L. Gauthier; Curtis R. Pickering; Caroline J. Miller; Colleen A. Fordyce; Karen L. Chew; Hal K. Berman; Thea D. Tlsty
The immediate-early gene, cyclooxygenase-2 (COX-2), is induced in a variety of inflammatory and neoplastic processes and is believed to play an important role in tumorigenesis. In this study, we identify an important upstream regulatory pathway of COX-2 expression in variant human mammary epithelial cells (vHMEC), which has been shown to exhibit phenotypes important for malignancy. We find that the stress-activated kinase, p38, is phosphorylated and activated in vHMEC compared with HMEC and is responsible for the expression of COX-2 in vHMEC as cells grow in culture. Furthermore in this capacity, p38 acts to stabilize the COX-2 transcript rather than activate COX-2 transcription. Inhibition of p38 kinase, using a chemical inhibitor, down-regulates COX-2 and decreases cell survival. Examination of archived tissue from women with ductal carcinoma in situ reveals epithelial cells that not only overexpress COX-2 but also have an abundance of activated phospho-p38 in the nucleus and cytoplasm, mirroring the expression observed in vitro. These epithelial cells are found within premalignant lesions as well as in fields of morphologically normal tissue that surround the lesions. In contrast, low phospho-p38 staining was observed in the majority of normal tissue obtained from reduction mammoplasty. These data help define the regulation of COX-2 expression in early carcinogenesis and provide alternative candidates for targeted prevention of COX-2-induced phenotypes and breast cancer.
Cancer Prevention Research | 2010
Hal K. Berman; Mona L. Gauthier; Thea D. Tlsty
As is well established in invasive breast disease, it is becoming increasingly clear that molecular heterogeneity, both between and within lesions, is a prevalent, distinct phenotype of premalignant lesions of the breast. Key pathways of tumorigenesis modulate critical features of premalignant lesions such as proliferation, differentiation, stress response, and even the generation of diversity. Current studies show that evaluation of these lesions may provide clinically useful information on future tumor formation as well as biological insights into the origin and functional significance of this distinct phenotype. Cancer Prev Res; 3(5); 579–87. ©2010 AACR.
Cancer Prevention Research | 2010
Colleen A. Fordyce; Tim Fessenden; Curtis R. Pickering; Jason Jung; Veena Singla; Hal K. Berman; Thea D. Tlsty
Cyclooxygenase-2 (COX-2) catalyzes the rate-limiting step in the synthesis of prostaglandins. Its overexpression induces numerous tumor-promoting phenotypes and is associated with cancer metastasis and poor clinical outcome. Although COX-2 inhibitors are promising chemotherapeutic and chemopreventative agents for cancer, the risk of significant cardiovascular and gastrointestinal complications currently outweighs their potential benefits. Systemic complications of COX-2 inhibition could be avoided by specifically decreasing COX-2 expression in epithelial cells. To that end, we have investigated the signal transduction pathway regulating the COX-2 expression in response to DNA damage in breast epithelial cells. In variant human mammary epithelial cells that have silenced p16 (vHMEC), double-strand DNA damage or telomere malfunction results in a p53- and activin A–dependent induction of COX-2 and continued proliferation. In contrast, telomere malfunction in HMEC with an intact p16/Rb pathway induces cell cycle arrest. Importantly, in ductal carcinoma in situ lesions, high COX-2 expression is associated with high γH2AX, TRF2, activin A, and telomere malfunction. These data show that DNA damage and telomere malfunction can have both cell-autonomous and cell-nonautonomous consequences and can provide a novel mechanism for the propagation of tumorigenesis. Cancer Prev Res; 3(2); 190–201
Cancer Cell | 2007
Mona L. Gauthier; Hal K. Berman; Caroline J. Miller; Krystyna Kozakeiwicz; Karen Chew; Dan H. Moore; Joseph T. Rabban; Yunn Yi Chen; Karla Kerlikowske; Thea D. Tlsty
Journal of Clinical Oncology | 2007
Amy C. Degnim; Daniel W. Visscher; Hal K. Berman; Marlene H. Frost; Thomas A. Sellers; Robert A. Vierkant; Shaun D. Maloney; V. Shane Pankratz; Piet C. de Groen; Wilma L. Lingle; Karthik Ghosh; Lois Penheiter; Thea D. Tlsty; L. Joseph Melton; Carol Reynolds; Lynn C. Hartmann
Cold Spring Harbor Symposia on Quantitative Biology | 2005
Hal K. Berman; Jianmin Zhang; Yongping Crawford; Mona L. Gauthier; Colleen A. Fordyce; Kimberly M. McDermott; Mahvash Sigaroudinia; Krystyna Kozakiewicz; Thea D. Tlsty
Archive | 2011
Karla Kerlikowske; Thea D. Tlsty; Mona L. Gauthier; Hal K. Berman; Troy Bremer; Annette M. Molinaro
Archive | 2007
Thea D. Tlsty; Hal K. Berman; Mona L. Gauthier; Bob Y. Liu; Colleen A. Fordyce; Curtis R. Pickering; Paul A Reynolds; Nancy Dumont; Geoffrey M. Benton
Archive | 2007
Thea D. Tlsty; Hal K. Berman; Mona L. Gauthier; Bob Y. Liu; Colleen A. Fordyce; Curtis R. Pickering; Paul A Reynolds; Nancy Dumont; Geoffrey M. Benton
Archive | 2007
Thea D. Tlsty; Hal K. Berman; Mona L. Gauthier; Bob Y. Liu; Colleen A. Fordyce; Curtis R. Pickering; Paul A Reynolds; Nancy Dumont; Geoffrey M. Benton